Loading
A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch is a phase 1 interventional study registered as NCT03778047 by Hinova Pharmaceuticals Inc., with 10 participants enrolled, started 2018-02-07. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: Enzalutamide and HC1119.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/